We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Board Members Join PolyTherics
News

New Board Members Join PolyTherics

New Board Members Join PolyTherics
News

New Board Members Join PolyTherics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Board Members Join PolyTherics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PolyTherics Limited has announced that Dr Anker Lundemose and Nigel Pitchford have joined its Board.

Dr Lundemose is co-founder of several companies including Symphogen A/S and Santaris A/S and was co-founder and CEO of Prosidion Ltd, a UK subsidiary of OSI Pharmaceuticals Inc. He is also a former managing director of OSI’s venture capital arm.

Dr Lundemose is medically qualified and has a PhD in molecular biology. He started his industry career in research with Novo Nordisk before moving into business development and has an international reputation in R&D productivity and for executing high profile licensing and M&A deals.

Nigel Pitchford is Managing Director of Healthcare Investments at Imperial Innovations Group plc. Nigel brings many years of experience as a venture capital investor to the PolyTherics board, drawn from his time with 3i and DFJ Esprit.

Ken Cunningham, Chairman of PolyTherics, welcomes Nigel and Anker to the board, saying, “As PolyTherics makes significant commercial progress with its expanded technology offering and its increasingly successful licensing strategy, these valuable additions to the Board set up the company for its next phase of development.”

Advertisement